Trials / Completed
CompletedNCT05113693
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 in Healthy Volunteers Under Fed Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years – 54 Years
- Healthy volunteers
- Accepted
Summary
Objective \- Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-393 | QD, PO |
| DRUG | CKD-501, D759, H053 | QD, PO |
Timeline
- Start date
- 2021-11-25
- Primary completion
- 2021-12-06
- Completion
- 2021-12-10
- First posted
- 2021-11-09
- Last updated
- 2023-06-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05113693. Inclusion in this directory is not an endorsement.